17 research outputs found
A case report of severe panhypopituitarism in a newborn delivered by a women with Turner syndrome
Prepubertal ultra-low-dose estrogen therapy is associated with healthier lipid profile than conventional estrogen replacement for pubertal induction in adolescent girls with Turner syndrome : preliminary results
estrogen replacement (LE) therapy in Turner syndrome
(TS) have not been fully investigated to date. The present
study aimed to compare glucose and lipids metabolism
in adolescents with TS on LE and conventional estrogen
replacement (CE).
Methods In 14 TS (mean age 13.8), LE (-estradiol,
62.5 g daily) was introduced before age 12 (mean age
10.5), and followed by a pubertal induction regimen after
age 12, and in 14 CE was started after age 12 (mean 14,
SD 1.96). Before, and 3 years after starting -estradiol
growth velocity, bone age, BMI, and selected parameters of
glucose and lipids metabolism were assessed.
Results There were no significant differences between LE
and CE in the mean levels of any parameter before introduction
of -estradiol [total cholesterol (TC): 4.1 vs
4.3 mmol/L, LDL cholesterol (LDLc): 2.2 vs 2.4 mmol/L,
HDL cholesterol (HDLc): 1.6 vs 1.4 mmol/L, triglycerides:
0.9 vs 1.0 mmol/L, fasting glucose: 4.2 vs 4.4 mmol/L,
post-load glucose: 4.8 vs 5.5 mmol/L; fasting insulin: 6.8
vs 8.0 post-load insulin: 21.3 vs 67.0 IU/mL, HOMAIR
1.3 vs 1.6]. After three years of treatment, TC and
LDLc levels were significantly lower in LE group (3.8 vs
4.4 mmol/L, p = 0.004; 1.9 vs 2.4 mmol/L, p = 0.03). The
other parameters did not differ significantly. There was no negative impact on growth course and bone age advancement
nor on BMI in LE group.
Conclusion Prepubertal LE is associated with healthier
lipid profile than CE in girls with TS
High incidence of abnormal circadian Bood Pressure profiles in patients on steroid replacement therapy due to Secondary Adrenal Insufficiency and Congenital Adrenal Hyperplasia without overt hypertension : initial results
that disruptions in the cortisol diurnal rhythm may affect the blood pressure (BP) profile.
Aim: To evaluate the circadian BP profiles of patients with secondary adrenal insufficiency (SAI) and congenital
adrenal hyperplasia (CAH) on steroid replacement therapy and to compare BP profiles of patients receiving
hydrocortisone (HC) in different dosing schedules.
Methods: The study included 33 patients: 15 SAI and 18 CAH (mean age 13.2 years 95CI 11.3-15.1). There were
no patients with previously diagnosed overt hypertension. Patients with SAI received a mean of 7.39 mg/m2
of HC in 3
daily doses (in the morning (M) 50%, in the afternoon (A) 25%, in the evening (E) 25%), CAH patients 17.9 mg/m2
of HC
in the following dosing schedules: 5 patients in 3 equal doses, 7 patients received M: 40% A: 40% E: 20%, the remaining
6 patients had the same dosing schedule as patients with SAI. Fludrocortisone (FC) was given to 13 patients with CAH
in 2 equal daily doses. The total dose of HC/FC as well as the dosing schedule of HC was adjusted individually based
on clinical and biochemical outcomes. Standard 24-hour BP monitoring (ABPM) was performed using an Ambulatory
BP Monitor (Space labs 90217, USA).
Results: The majority of the patients (almost 70% SAI, 80% CAH) presented with an abnormal 24-hour BP profile.
There were no significant differences in ABPM results between SAI and CAH patients, and no differences between
CAH patients treated with and without FC. There was no correlation between HC and FC doses [mg/m2
] and ABPM
results except that mean night SBP values increased with greater HC doses (r=0.51, p<0.05). Among the CAH group
the highest percentage of abnormal ABPM results was observed in patients who received HC in doses: M: 50% A: 25%
and E: 25%, the most favorable BP profile was observed in patients with dosing schedule: M: 40%, A: 40%, E: 20%.
However there were no significant differences between patients with different treatment protocols, the results suggest
that observed disruptions of the BP profile could be related to the HC dosing schedule.
Conclusions: The incidence of abnormal BP profiles in patients on steroid replacement therapy due to SAI and
CAH without overt hypertension is high. The disruptions of the BP profiles are not associated with the dose of HC or
FC. The abnormal BP profiles in patients with SAI or CAH may be related to the HC dosing schedule. 24-hour ABPM
seems to be a useful, non-invasive and safe method for the monitoring of HC and FC replacement therapy in patients
with adrenal insufficiency. Further investigations in the larger groups of patients are needed
Human recombinant growth hormone normalizes growth and alleviates symptoms in children with severe growth deficit treated with glycocortisteroids due to Crohn’s disease - case presentation
Choroba Le艣niowskiego-Crohna (CD) jest przyczyn膮 niskiego wzrostu
u 10–20% chorych w wyniku katabolicznego dzia艂ania: 1) niedo偶ywienia
spowodowanego upo艣ledzeniem wch艂aniania oraz jelitow膮
utrat膮 bia艂ka, 2) przewlek艂ego procesu zapalnego, kt贸ry wywo艂uje
zale偶n膮 od TNF-a oporno艣膰 na hormon wzrostu (GH) oraz
3) przewlek艂ej kortykoterapii hamuj膮cej dzia艂anie osi somatotropowej.
Autorzy niniejszej pracy przedstawi膮 przypadek 14-letniego
ch艂opca z CD, oty艂o艣ci膮 (+55%) o typie cushingoidalnym i nadChoroba Le艣niowskiego-Crohna (CD) jest przyczyn膮 niskiego wzrostu
u 10–20% chorych w wyniku katabolicznego dzia艂ania: 1) niedo偶ywienia
spowodowanego upo艣ledzeniem wch艂aniania oraz jelitow膮
utrat膮 bia艂ka, 2) przewlek艂ego procesu zapalnego, kt贸ry wywo艂uje
zale偶n膮 od TNF-a oporno艣膰 na hormon wzrostu (GH) oraz
3) przewlek艂ej kortykoterapii hamuj膮cej dzia艂anie osi somatotropowej.
Autorzy niniejszej pracy przedstawi膮 przypadek 14-letniego
ch艂opca z CD, oty艂o艣ci膮 (+55%) o typie cushingoidalnym i nadci艣nieniem
t臋tniczym, kt贸rego leczono od 7 r偶. glikokortykoidami
(GCS) (prednizon 2 mg/kg/d., metylprednizolon 0,1–0,6 mg/kg/d.),
od 9 r偶. mesalazyn膮 (0,02–0,2 mg/kg/d.), od 14 r偶. azatiopryn膮
(1–2 mg/kg/d.), a od 15 — 4/12 ludzkim rekombinowanym hormonem
wzrostu (rhGH) (1 j./kg/tydz.) z powodu rozpoznania izolowanego
niedoboru GH na podstawie niedoboru wzrostu –4 SDS,
op贸藕nienia wieku kostnego (9 lat), zahamowania wzrastania
(0,0 cm/rok) w okresie ostatnich 2 lat oraz maksymalnego wyrzutu
GH poni偶ej 10 ng/ml w dw贸ch testach farmakologicznych. Pacjent
otrzymywa艂 ponadto analog GnRH (Diphereline 3,75 mg/4 tyg.)
z powodu nasilonych w ci膮gu ostatnich 2 lat cech pokwitania (obj臋to艣膰
j膮der po 8 ml, maks. wyrzut LH = 9,1 mj./ml po do偶ylnej
stymulacji 100 μg GnRH). W czasie trwaj膮cego 3,5 roku leczenia
rHGH uzyskano st臋偶enia IGF-1 zbli偶one do +2 SD oraz szybko艣膰
wzrastania (maks. 9,7 cm/rok), mimo r贸wnoczesnego stosowania
GCS, wzrost ko艅cowy (174 cm, –0,2 SDS), zgodny ze wzrostem
docelowym (176,5 cm), oraz remisj臋 choroby zasadniczej, pozwalaj膮c膮 na redukcj臋, a nast臋pnie ca艂kowite odstawienie GCS.
Nie obserwowano zaburze艅 gospodarki w臋glowodanowej (glikemia
na czczo 5,4 mmol/l, HbA1c 5,1%). Na podstawie tych obserwacji
wykazano, 偶e leczenie rhGH przy zastosowanych dawkach
poprawia wzrost ko艅cowy i przebieg choroby u pacjent贸w z CD.Crohn’s disease (CD) causes short stature in 10-20% of patients
due to catabolic effects of: 1. malnutrition resulting from malabsorbtion
and intestinal protein loss, 2. chronic inflammatory process
triggered by TNF-alpha-dependent resistance to growth hormone
(GH), and 3. chronic corticoid therapy inhibiting the somatotropic
axis activity. The authors present a 14-year old boy with
CD, cushingoid-type obesity (+55%), hypertension, treated with
glucocortocoids (GCS) (prednizone 2 mg/kg/day, methylprednizolone
0.1-0.6 mg/kg/day) since 7 years of age, mesalazine (0.02-0.2 mg/kg/day) since 9 years of age, azatioprin (1-2 mg/kg/day)
since 14 years of age, and human recombinant growth hormone
(rhGH) (1 IU/kg/week) since 15 4/12 years of age due to isolated
GH deficiency diagnosed based on growth deficit -4 SDS, delayed
bone age (9 years), growth inhibition (0.0 cm/year) within the past
2 years, and maks. GH release below 10 ng/ml in two pharmacological
tests. Additionally, he received a GnRH analog (Diphereline
3.75 mg/4 weeks) due to intensified puberty signs noted over
the past 2 years (testicular volume - 8 ml each, max. LH surge
release 9.1 mIU/ml following IV stimulation with 100 μg GnRH).
Within 3.5 years of rHGH treatment, he demonstrated IGF-I levels
approximating IGF-I +2 SD, improved growth rate (max. 9.7 cm/year),
despite concomitant GCS administration, final height of 174 cm,
-0.2 SDS (in agreement with mean parental height - 176.5 cm)
and underlying disease remission, allowing for reducing the dose
and subsequent GCS termination. No carbohydrate metabolism disturbances
were seen (fasting glycemia 5.4 mmol/l, HbA1c 5.1%).
These observations indicate the employed doses of rhGH improve
final height and the course of disease in CD patients
The treatment of severe growth failure in children with juvenile idiopathic arthritis and growth hormone deficiency - preliminary results
WST臉P. Niedob贸r wzrostu nale偶y do g艂贸wnych niespecyficznych
objaw贸w m艂odzie艅czego idiopatycznego zapalenia staw贸w (JIA)
i dotyczy, w zale偶no艣ci od postaci i ci臋偶ko艣ci choroby, 11–90%
pacjent贸w. Wydaje si臋, 偶e u oko艂o 70% tych chorych mo偶e by膰
skuteczne leczenie ludzkim rekombinowanym hormonem wzrostu
(rhGH). Celem pracy by艂a ocena wst臋pnych wynik贸w leczenia
ci臋偶kiego niedoboru wzrostu w przebiegu JIA z towarzysz膮cym
niedoborem GH przy zastosowaniu rhGH.
MATERIA艁 I METODY. Spo艣r贸d 10 chorych (4 ch艂opc贸w,
6 dziewcz膮t) w wieku 6-15,5 (艣rednia 12,2 roku) z niedoborem
wzrostu [(-)7,7-(-2,4) SDS] do leczenia rhGH zakwalifikowano
5 chorych (2 ch艂opc贸w, 3 dziewczynki) na podstawie wykazania
u nich wsp贸艂istniej膮cego niedoboru GH. Wszyscy otrzymywali
glikokortykosteroidy (GKS) w 艣redniej dawce 0,08-1,4 mg/kg/24 h w przeliczeniu na prednizon, 3 chorych, u kt贸rych zastosowano
leczenie rhGH, oraz wszyscy nieleczeni rhGH otrzymywali ponadto lek blokuj膮cy czynnik martwicy nowotworu a
(Etanercept).
WYNIKI. W pierwszym roku leczenia rhGH w dawce 0,03-0,06, 艣rednio
0,047 mg/kg mc./dob臋, uzyskano zwi臋kszenie szybko艣ci wzrastania
z 0-3,2; 艣rednio 1 cm/rok do 0,3-16; 艣rednio 3,3 cm/rok,
wzrost st臋偶enia insulinopodobnego czynnika wzrostu typu 1
z 69,1-331,1; 艣rednio 197,5 ng/ml do 335-716,9; 艣rednio 526 ng/ml.
W trakcie 16,6 pacjentolat (5 pacjent贸w, indywidualny czas leczenia
1,8-4,5; 艣rednio 3,8 roku) w czterech przypadkach leczenie rhGH
spowodowa艂o zwi臋kszenia wysoko艣ci cia艂a o 0,1-2,2 SD. U chorych
nieleczonych rhGH nie obserwowano przyspieszenia wzrastania.
WNIOSKI. U chorych z JIA stosowanie rhGH w dawce zbli偶onej do
0,047 mg/kg mc./dob臋 poprawia szybko艣膰 wzrastania i wzrost ko艅cowy.
Wyniki leczenia mog膮 si臋 r贸偶ni膰 u poszczeg贸lnych chorych
z JIA i s膮 tym lepsze, im mniejszy jest niedob贸r wzrostu w momencie
rozpocz臋cia leczenia oraz mniejsze nasilenie procesu zapalnego.
S艂owa kluczowe: m艂odzie艅cze idiopatyczne zapalenie staw贸w,
niedob贸r wzrostu, hormon wzrostu
Endokrynologia, Oty艂o艣膰 i Zaburzenia Przemiany Materii 2010, tom 6, nr 2,
67-71INTRODUCTION. Short stature is one of the major, nonspecific
features of juvenile idiopathic arthritis (JIA), that affects, in dependence on clinical presentation and severity, 11-90% of patients. The
treatment with human recombinant growth hormone (rhGH) may
be successful in almost 70% of such cases. the aim of the study was
to analyze the initial results of the rhGH treatment in children with
severe growth failure and GH deficiency secondary to JIA.
MATERIAL AND METHODS. From among 10 children (4 boys,
6 girls), age 6-15.5, mean 12.2 years, with growth deficiency
[(-)7.7-(-2.4) the SDS], 5 (2 boys, 3 girls) with coexisting GH deficiency
received rhGH treatment. All patients were treated with glucocorticoids
(GCS) with a mean dosage of 0.08-1.4 mg/kg/day
(prednisone), 3 of the patients treated with rhGH, and all non-treated
patients received biological treatment (Etanercept).
RESULTS. After one year of rhGH treatment with a dosage of
0.03-0.06, mean 0.047 mg/kg/day) the growth velocity increased from
0–3.2, mean 1 cm/year, to 0.3-16, mean 3.3 cm/year, as well as the
insulin like growth factor type 1 concentration from 69.1-331.1 (mean
197.5) ng/ml to 335-716,9 (mean 526) ng/ml. In 16.6 patient-years of
treatment (5 patients, individual treatment period 1.8-4.5; mean 3.8 years)
there was improvement of growth from 0.1 to 2.2 SD in 4 cases.
CONCLUSIONS. In patients with JIA undergoing rhGH treatment,
with a dosage of approximately 0.047 mg/kg/day, improves growth
velocity, and final height. The results may be different in individual
cases. They are better if the growth failure before treatment is less
severe, and the inflammation process is less active.
Endocrinology, Obesity and Metabolic Disorders 2010, vol. 6, No 2, 67-7